Trial
NCT06463184
Study to Assess Xevinapant in Preoperative Subjects With Recurrent High-Grade Glioma (rHGG)
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Collaborators
EMD Serono Research & Development Institute, Inc.
Condition
Recurrent High-grade Glioma
Intervention
Xevinapant
Why stopped
funding issues
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-12-04